Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Tirumotecan for Previously Treated Unresectable Thymic Carcinomas
NCT07750353Phase 2Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2027
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
A Phase 2 trial of sacituzumab tirumotecan in thymic carcinoma (TC), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on NCT07750353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07750353.